Skip to main content
Clinical Trials/CTIS2023-505110-14-00
CTIS2023-505110-14-00Active, not recruitingPhase 1

A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects with Unresectable Metastatic Colorectal Cancer - M24-311

AbbVie Deutschland GmbH & Co. KG0 sites206 target enrollmentStarted: April 26, 2024Last updated:
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
206

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 65+ (—)
Sex
All

Inclusion Criteria

  • Diagnosis of histologically or cytologically confirmed unresectable metastatic colorectal cancer (mCRC)., Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Exclusion Criteria

  • Harbor the BRAF V600E mutation., dMMR+/MSI-H., Progressed on only one first-line (1L) systemic treatment of combination chemotherapy in the metastatic setting with or without targeted therapy., Received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 28 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of ABBV-400.

Investigators

Similar Trials

Active, not recruiting
Phase 1
A Study Evaluating Venetoclax in Combination with Azacitidine Compared with Azacitidine Alone in Subjects with Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS)
EUCTR2016-001657-41-DEAbbVie Deutschland GmbH & Co. KG90
Active, not recruiting
Phase 1
A Study Evaluating Venetoclax in Combination with Azacitidine Compared with Azacitidine Alone in Subjects with Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS)
EUCTR2016-001657-41-GBAbbVie Deutschland GmbH & Co. KG90
Active, not recruiting
Phase 1
Evaluating Avelumab in combination with Cetuximab in Head and neck cancer (EACH)recurrent/metastatic head and neck squamous cell cancerMedDRA version: 20.0 Level: PT Classification code 10067821 Term: Head and neck cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10060121 Term: Squamous cell carcinoma of head and neck System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2017-003592-64-GBniversity College London130
Active, not recruiting
Phase 1
A study investigating the safety, absorption and elimination of FM101, a new compound in the treatment of non-alcoholic fatty liver disease.onalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)MedDRA version: 22.0Level: LLTClassification code 10029530Term: Non-alcoholic fatty liverSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disorders
EUCTR2020-005187-63-HUFuture Medicine Co., Ltd.60
Active, not recruiting
Phase 1
A study investigating the safety, absorption and elimination of FM101, a new compound in the treatment of non-alcoholic fatty liver disease.onalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)MedDRA version: 22.0Level: LLTClassification code 10029530Term: Non-alcoholic fatty liverSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disorders
EUCTR2020-005187-63-ESFuture Medicine Co., Ltd.60